Prenetics Global Limited (NASDAQ:PRE - Get Free Report) CEO Danny Sheng Wu Yeung acquired 7,500 shares of Prenetics Global stock in a transaction on Thursday, August 20th. The shares were purchased at an average price of $18.31 per share, with a total value of $137,325.00. Following the completion of the purchase, the chief executive officer owned 95,235 shares in the company, valued at $1,743,752.85. This represents a 8.55% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Danny Sheng Wu Yeung also recently made the following trade(s):
- On Monday, August 24th, Danny Sheng Wu Yeung bought 17,181 shares of Prenetics Global stock. The stock was purchased at an average cost of $21.23 per share, with a total value of $364,752.63.
Prenetics Global Stock Performance
Shares of NASDAQ PRE opened at $21.82 on Tuesday. The firm's 50 day moving average price is $19.07 and its 200-day moving average price is $18.90. The company has a market cap of $368.19 million, a PE ratio of -5.25 and a beta of 0.26. Prenetics Global Limited has a 52-week low of $7.18 and a 52-week high of $23.63.
Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.31. The firm had revenue of $46.49 million for the quarter, compared to analysts' expectations of $49.85 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. On average, analysts forecast that Prenetics Global Limited will post -1.86 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have commented on the company. Wall Street Zen raised Prenetics Global from a "sell" rating to a "hold" rating in a report on Saturday. Benchmark upped their price target on Prenetics Global from $30.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Prenetics Global in a research report on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.25.
Get Our Latest Stock Analysis on PRE
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the stock. 683 Capital Management LLC purchased a new stake in Prenetics Global in the fourth quarter worth approximately $1,181,000. T3 Companies LLC purchased a new position in Prenetics Global in the fourth quarter worth about $170,000. Kingsview Wealth Management LLC bought a new stake in shares of Prenetics Global during the 4th quarter valued at about $172,000. Renaissance Technologies LLC increased its position in shares of Prenetics Global by 85.1% during the 1st quarter. Renaissance Technologies LLC now owns 31,322 shares of the company's stock valued at $605,000 after purchasing an additional 14,400 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new position in shares of Prenetics Global in the 4th quarter worth approximately $241,000. 25.01% of the stock is owned by hedge funds and other institutional investors.
About Prenetics Global
(
Get Free Report)
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
